South Korean biotech company Bridge Biotherapeutics Inc and its JLABS TMC (Houston, Texas) company announced on Friday the successful submission of an Investigational New Drug (IND) application for BBT-877 drug candidate for Idiopathic Pulmonary Fibrosis (IPF) with the US Food and Drug Administration (FDA).
Idiopathic Pulmonary Fibrosis (IPF) is reportedly a progressive, irreversible and fatal lung disease.
BBT-877, a potent and selective Autotaxin (ENPP) inhibitor is being developed potentially for the treatment of various fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH). BBT-877 is reportedly the second molecule from Bridge Biotherapeutics.
In January 2019, Bridge Biotherapeutics plans to start a Phase I study of BBT-877 to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the drug candidate in healthy volunteers in the US. The planned study will be performed in two phases, a Single Ascending Dose (SAD) phase with five cohorts and a Multi Ascending Dose (MAD) phase with three cohorts. The estimated primary completion date is currently expected in late 2019.
Additionally, Bridge Biotherapeutics presented the results of the preclinical study on BBT-877 at the IPF Summit in August 2018, attracting pulmonologists' interest on the efficacy and safety of the drug candidate. The data has demonstrated the best-in-class opportunity in comparison to a current development pipeline compound.
Concurrently, Bridge is developing BBT-401, the first anti-Pellino-1 compound for the ulcerative colitis and aims to initiate the Phase II study in the US within this year.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients